Protected: Gilead agrees funding with Federal Government for Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for second-line treatment of relapsed or refractory large b-cell lymphoma (LBCL)^(1,2)

By ONA Editor December 3, 2024 No Comments

$Protected: Gilead agrees funding with Federal Government for Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for second-line treatment of relapsed or refractory large b-cell lymphoma (LBCL)(1,2)$

About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

This post is password protected. Enter the password to view comments.

About Author

Related Posts

New CAR-T cell therapy shows promise for hard-to-treat cancers

Gene modification could improve cancer treatment’s success rate

FDA approves brentuximab vedotin with lenalidomide and rituximab for relapsed or refractory large B-cell lymphoma